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Abstract: In melanoma, one of the most aggressive human tumors, early diagnosis is still the best strategy to increase 
survival rates. C57/B1 and B16-F0 are murine cell lines frequently applied in basic and applied melanoma research. Thus, 
it is striking, that cytogenomic features of these two cell lines are not known yet. In the present study, molecular 
cytogenetics and array-comparative genomic hybridization were done in C57/B1 and B16-F0 cells and the resulting 
imbalances and breakpoints were translated into the human genome. Both cell lines derived from each other and had an 
isochromosome 12 and a balanced translocation of chromosomes 3 and 13 in common. Interestingly, both cell lines 
presented aberrations which were also observed in human skin but not in human eye or uveal melanoma. 
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INTRODUCTION 
One of the most aggressive human cancer types with 
adverse prognosis are skin cancers, with melanomas of 
skin and eye being most frequently observed subtypes.1 
Most deleterious forms of melanoma accompany the 
metastatic stage, while at early stages the small tumors 
can be treated by simple surgical removal.2-4 Most 
important underlying reason for skin cancers is 
excessive exposure to ultraviolet (specifically UVB) 
light.5 This can cause inflammation, DNA mutations and 
damage, and go together with chromothripsis-related 
events and/or cell death. It is a truism that during 
initiation, promotion and progression of skin cancer, 
changes in DNA and chromosomes are involved.6 Thus, 
genetic studies are necessary to better understand 
melanoma biology, which also need to be combined 
with tests of novel melanoma therapeutics.5 
Genes recently brought to the focus of melanoma 
research were those involved in pigmentation, DNA 
repair,  immune response, metabolism and/or are 
vitamin D receptor polymorphisms.1, 7 Also specifically 
associated with hereditary melanomas are the so-called 
high- (CDKN2A, CDK4, TERT, POT1), moderate- 
(MC1R, MITF) and low-penetrance genes (KIT, SOX10, 
MDM2), known to be able to act as tumor suppressor 
genes or oncogenes. Still, molecular genetic diagnostics 
was not routinely considered in skin cancer treatment, as 
no significant influence on overall survival rates could 
be achieved by inclusion of genetic data in the past.3, 7, 8 
Nowadays, BRAF and MEK inhibitors, which are based 
on genetic data regarding mutations in the BRAF gene, 
are well-established, standard and successful treatments 
for metastatic melanoma.9 
In melanoma, as in other cancer research, there is a need 
for in vivo and in vitro model systems. This can include 
model animals, and, among them, murine model 
systems are still the most preferred ones.10 A special 
form of murine model systems are cell lines. Most 
interestingly, murine tumor cell lines like B16-F0 and 
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melanoma models.11 C57/B1 and B16-F0 derive from a 
naturally occurring melanoma in the syngeneic 
C57BL/6 (H-2b) mouse strain – the gender of the mouse 
is not reported.12 These C57/B1 and B16-F0 cells were 
taken in cell culture in 1954.13 Still, these two cell lines 
have been applied without any detailed genetic 
characterization to date. Here, we performed the first 
cytogenomic characterization of C57/B1 and B16-F0 
based on molecular cytogenetic and array-comparative 
genomic hybridization (aCGH) approaches. 
 
 
MATERIAL AND METHODS 
Cell lines 
The cell lines C57/B1 and B16-F0 were obtained from 
the European Collection of Authenticated Cell Cultures 
(ECACC 92101204 and ECACC 85011438; Salisbury, 
UK). They are indicated there as ‘not further 
characterized salivary tumor lines’ to be grown 
adherently (medium: DMEM/10% fetal calf serum + 
antibiotics). Cells were prepared cytogenetically14 and 
whole genomic DNA was extracted as described 
elsewhere.15 Cell line-derived chromosomes were 
subjected to molecular cytogenetics, and extracted DNA 




Fluorescence in situ hybridization (FISH) was 
performed using whole chromosome paints 
(“SkyPaintTM DNA Kit M-10 for Mouse 
Chromosomes”, Applied Spectral Imaging, Edingen-
Neckarhausen, Germany) in multicolor-FISH (mFISH), 
and murine chromosome-specific multicolor banding 
(mcb) probe mixes for FISH-banding16, as previously 
described.17 For each probe set, at least 30 metaphases 
were documented and analyzed using Zeiss Axioplan 
microscopy, equipped with standard black and white 
CCD-camera and ISIS software (MetaSystems, 
Altlussheim, Germany). aCGH was done according to 
standard procedures using “SurePrint G3 Mouse CGH 





Karyotypes, breakpoints and imbalances observed in 
murine cell lines C57/B1 and B16-F0 were determined 
according to aCGH and mcb data and aligned to human 
homologous regions using Ensembl Browser.17 The 
obtained data was compared to genetic changes known 
from human malignant melanoma according to Höglund 
et al. (2004)1 and Di Lorenzo et al. (2016).7 
 
RESULTS 
Molecular cytogenetic results 
C57/B1 
C57/B1 is a rather stable diploid cell line. Despite that, 
this cell line showed five clones. Clone 1 (20%), which 
could be the ancestor clone, showed the following 
karyotype: 40,X,t(3;13)(F3;A3),dic(5;15)(A1;A1),+6, 
+6,idic(12)(A1;A1). Clone 2, with 25%, had the 
karyotype 39,X,idem,idic(16)(A1;A1). The karyotype 
of clone 3 (30%) was 40,X,idem,idic(18)(A1;A1) and is 
shown in Figure 1A. In clone 4 (20%), a complex 
derivative chromosome 13 replaced the 




there was a clone 5 with 40,X,idem,idic(10)(A1;A1) in 




B16-F0 is a tetraploid cell line with 71-77 chromosomes 
per metaphase. According to that, the karyotype of the 








In clone 2, a der(4)(pter→D2::A1→C5:) replaced one 
normal chromosome 4 - except for that, clone 2 was as 




aCGH-analysis of imbalanced rearrangements 
confirmed most of the FISH-detected aberrations 
(Figure 3). For more information about aCGH results 
and for the two cell lines, see Suppl. Table. Interestingly, 
clone 5 of C57/B1 seemed to be present in higher 
percentages in non-dividing cells than in dividing ones: 
in aCGH a trisomy 10, caused by idic(10)(A1;A1) and 
seen only in 5% of the metaphases, was clearly visible. 
The imbalance patterns of the murine melanoma cell 
lines C57/B1 and B16-F0 revealed by aCGH were 
translated to the human genome as depicted in Figure 4. 
By comparing the corresponding homologous regions 
for the cell lines in the human karyotype with the 
imbalances in malignant melanomas1, a resemblance 
was detected with skin melanoma (Table 1). Moreover, 
the loss of chromosome 3, and gain of 8q18 typical for 
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Figure 1. Molecular cytogenetic results in cell line C57/B1 
A) mFISH result using all murine whole chromosome painting probes 
in one experiment is depicted revealing a near-diploid karyotype. The 
karyotype formula for clone 3 is 40,X,t(3;13)(F3;A3),dic(5;15) 
(A1;A1),+6,+6,idic(12)(A1;A1),idic(18)(A1;A1). 
B) For C57/B1 clone 4 pseudocolor banding for murine chromosomes 
3 and 13 is shown. One normal chromosome 3 and 13 together with a 
der(3)t(3;13)(F3;A3) and a der(13)t(3;13)(3::13::13::3)(3qter→3F3:: 




Figure 2. Molecular cytogenetic results in cell line B16-F0 
A) mFISH results using all murine whole chromosome painting probes 
in one experiment revealed a near-tertaploid karyotype. Here shown is 
clone 2. 
B) Results for murine multicolor banding (mcb) using a chromosome 
4-, 17- and 19-specific probe are shown. mcb4 revealed a 
inv(4)(A1C1) and a der(4)(pter→D2::A1→C5:). The other 2 mcb 
probes identified four normal chromosomes 17, two normal 












Figure 3. A) aCGH results for murine melanoma cell line C57/B1. The copy number alterations with respect to the diploid karyotype are given as 
color code depicted in the figure with shades of red (losses) and green (gains), purple arrows indicate breakpoints. Breakpoints are indicated according 
to mcb results; B) Projection of the aCGH results for the cell line onto the human genome showing imbalances as gains and losses of specific 









Figure 4. aCGH results for murine melanoma cell line B16-F0 (A) and its projection onto the human genome (B). 
For more details see legend of Figure 3. 
 
 
In Table 2, locations of known low-, moderate- and 
high-penetrance genes associated with hereditary 
malignant melanomas were aligned with the imbalances 
found in C57/B1 and B16-F0. Four imbalances, each, 




Table 1. Most frequent aberrations of malignant melanoma (MM) 







-1p10-p36 28 29 + - 
+2 11 11 (+) (+) 
+3 18 10 (+) (+) 
-4 33 16 - + 
+4q27-q35 9 10 + - 
-5 32 16 - (+) 
+7 36 26 (+) (+) 
-8p10-p23 25 29 - (+) 
+8q10-q24 25 38 - + 
+9q22-q34 15 8 - + 
-12q13-q24 27 14 - (+) 
+12q15-q24 5 10 + - 
-14 35 18 - (+) 
+17q10-q25 12 9 - + 
+18 26 13 + - 
+19 14 8 (+) - 
+22 11 13 (+) - 
-X 23 22 - (+) 
OVERALL    
+ and (+) 
- - 9 12 




Melanomas constitute aggressive cancers and are 
mainly caused by UV exposure. Still, melanoma 
pathogenesis as well as progression are poorly 
understood, and effective treatment based on genetic 
data (mutations in BRAF gene) has only been developed 
in recent years.9 Here we studied the two murine 
melanoma cell lines derived from each other, C57/B1 
and B16-F0, for the first time. These studies were 
urgently needed, as e.g. B16-F0 was used in some 
studies as a model for cells with ‘poorly invasive’ 
features19 and in others as a model for studying the 
metastatic spread of melanoma.20 
Here it could be shown that the studied cell lines known 
to derive from each other have cytogenetic features in 
common, like an isochromosome 12 and a balanced 
translocation of chromosomes 3 and 13. However, 
C57/B1 is near-diploid and has much less chromosomal 
aberrations and imbalances than B16-F0. Interestingly, 
C57/B1 mainly had gains relative to its diploid 
karyotype, while B16-F0, presenting a near-tetraploid 
constitution, has both – gains and losses of copy 
numbers. Overall,  both cell lines are, according to  
Table 11, genetically most similar to human skin 
melanoma and have very little similarity to eye 
melanoma.  
A comparison of genomic regions known to comprise 
low-, moderate- and high-penetrance genes associated 
with hereditary malignant melanomas (Table 2) 
revealed gains of copy numbers for MITF and POT1 in 
C57/B1 and B16-F0; both genes are moderate- to high-
penetrance genes. However, MDM2 (low-penetrance 
gene) and CDK4 (high-penetrance gene) were amplified 
only in C57/B1, while KIT (low-penetrance gene) and 
CDKN2A (high-penetrance gene) showed loss or gain of 
copy numbers in B16-F0 (Table 2). Accordingly, no 
clear conclusions could be drawn from this data alone.  
Sequencing or expression profiling of the cell lines may 
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Table 2. Selected high-, moderate and low-penetrance genes playing a role in MM are listed. 
 gene location in human (GRCH37/hg19) C57/B B16-F0 
low-penetrance genes 
KIT chr4:55524095-55606881 no change loss 
MDM2 chr12:69201971-69239320 gain no change 
SOX10 chr22:38368319-38380539 no change no change 
moderate-penetrance genes 
MITF chr3:69788586-70017488 gain gain 
MC1R chr16:89984287-89987385 no change no change 
high-penetrance genes 
TERT chr5:1,253,287-1,295,162 no change no change 
POT1 chr7:124,462,440-124,570,037 gain gain 
CDKN2A chr9:21967751-21994490 no change gain 
CDK4 chr12:58141510-58146230 gain no change 
Legend: It is listed if the corresponding region is altered (gain, loss or no change) in the two cell lines. 
 
 
these genes. Interestingly, in 2008 Gobeil et al.21 used a 
genome wide RNAi screen for B16-F0, without 
knowing its genetic constitution, to identify the tumor 
suppressor gene GAS1. This was most likely successful, 
as GAS1, located in humans on chromosome 9q21.33, is 
not affected by copy number variations in B16-F0, acc. 
to our data (Suppl. Table 1). Another study using B16-
F0 worth mentioning is that of Yun et al. (2019)22: they 
selected this cell line for studies of the MITF gene - 
obviously without knowing that this gene is amplified in 
B16-F0. Thus, a new interpretation of their results may 
be necessary. 
In conclusion, here we performed the first detailed 
cytogenomic study in the murine malignant melanoma 
cell lines C57/B1 and B16-F0 and can conclude that they 
can be used as models for human metastatic melanoma 
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